



Miltenyi Biotec

Reference list

Myeloid cells in cancer research

Myeloid cells in the tumor microenvironment (human)

- Bergenfelz, C. *et al.* (2012) Wnt5a induces a tolerogenic phenotype of macrophages in sepsis and breast cancer patients. *J. Immunol.* 188: 5448.
<https://doi.org/10.4049/jimmunol.1103378>
- Bergenfelz, C. *et al.* (2013) Wnt5a inhibits human monocyte-derived myeloid dendritic cell generation. *Scand. J. Immunol.* 78: 194.
<https://doi.org/10.1111/sji.12075>
- Chimal-Ramírez, G. K. *et al.* (2016) Monocyte differentiation towards protumor activity does not correlate with M1 or M2 phenotypes. *J. Immunol. Res.* 2016.
<https://doi.org/10.1155/2016/6031486>
- Duluc, D. *et al.* (2009) Interferon- γ reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages. *Int. J. Cancer* 125: 367.
<https://doi.org/10.1002/ijc.24401>
- Estko, M. *et al.* (2015) Tumor cell derived effects on monocyte/macrophage polarization and function and modulatory potential of viscum album lipophilic extract *in vitro*. *BMC Complement. Altern. Med.* 15: 130.
<https://doi.org/10.1186/s12906-015-0650-3>
- Feng, A. L. *et al.* (2011) CD16⁺ monocytes in breast cancer patients: Expanded by monocyte chemoattractant protein-1 and may be useful for early diagnosis. *Clin. Exp. Immunol.* 164: 57–65.
<https://doi.org/10.1111/j.1365-2249.2011.04321.x>
- Figel, A. M. *et al.* (2011) Human renal cell carcinoma induces a dendritic cell subset that uses T cell crosstalk for tumor-permissive milieu alterations. *Am. J. Pathol.* 179: 436–451.
<https://doi.org/10.1016/j.ajpath.2011.03.011>
- Fiorcari, S. *et al.* (2015) Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia. *Haematologica* 100: 253–262.
<https://doi.org/10.3324/haematol.2014.113217>
- Giallongo, C. *et al.* (2014) Myeloid-derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients. *PLoS ONE* 9: 101848.
<https://doi.org/10.1371/journal.pone.0101848>
- Gielen, P. R. *et al.* (2015) Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue. *J. Neuropathol. Exp. Neurol.* 74: 390–400.
<https://doi.org/10.1097/NEN.0000000000000183>
- Giordano, C. *et al.* (2021) Combining magnetic resonance imaging with systemic monocyte evaluation for the implementation of gbm management. *Int. J. Mol. Sci.* 22: 3797.
<https://doi.org/10.3390/ijms22073797>
- Gustafson, M. P. *et al.* (2015) Intratumoral CD14⁺ cells and circulating CD14⁺HLA-DR^{lo/neg} monocytes correlate with decreased survival in patients with clear cell renal cell carcinoma. *Clin. Cancer Res.* 21: 4224–4233.
<https://doi.org/10.1158/1078-0432.CCR-15-0260>
- Hoechst, B. *et al.* (2008) A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4⁺CD25⁺Foxp3⁺ T cells. *Gastroenterology* 135: 234–243.
<https://doi.org/10.1053/j.gastro.2008.03.020>
- Horzum, U. *et al.* (2021) CD66b⁺ monocytes represent a proinflammatory myeloid subpopulation in cancer. *Cancer Immunol. Immunother.* 70: 75–87.
<https://doi.org/10.1007/s00262-020-02656-y>

- Jordan, K. R. *et al.* (2017) Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients. *Cancer Immunol. Immunother.* 66: 503–513.
<https://doi.org/10.1007/s00262-016-1953-z>
- Kobayashi, M. *et al.* (2019) Blocking monocytic myeloid-derived suppressor cell function via anti-DC-HIL/GpNMB antibody restores the *in vitro* integrity of T cells from cancer patients. *Clin. Cancer Res.* 25: 828–838.
<https://doi.org/10.1158/1078-0432.CCR-18-0330>
- Kotsakis, A. *et al.* (2012) Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. *J. Immunol. Methods* 381: 14–22.
<https://doi.org/10.1016/j.jim.2012.04.004>
- Kuwana, M. *et al.* (2006) Endothelial differentiation potential of human monocyte-derived multipotential cells. *Stem Cells* 24: 2733–2743.
<https://doi.org/10.1634/stemcells.2006-0026>
- Lindenberg, J. J. *et al.* (2013) IL-10 conditioning of human skin affects the distribution of migratory dendritic cell subsets and functional T cell differentiation. *PLoS ONE* 8: 70237.
<https://doi.org/10.1371/journal.pone.0070237>
- Maeda, R. *et al.* (2014) Circulating CD14⁺CD204⁺ cells predict postoperative recurrence in non-small-cell lung cancer patients. *J. Thorac. Oncol.* 9: 179–88.
<https://doi.org/10.1097/JTO.000000000000044>
- Marques, G. S. *et al.* (2018) Antitumor efficacy of human monocyte-derived dendritic cells: comparing effects of two monocyte isolation methods. *Biol. Proced. Online* 20.
<https://doi.org/10.1186/s12575-018-0069-6>
- Mougiakakos, D. *et al.* (2013) Immunosuppressive CD14⁺ HLA-DR^{low/neg} IDO⁺ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation. *Leukemia* 27: 377–388.
<https://doi.org/10.1038/leu.2012.215>
- Nieda, M. *et al.* (2015) Effective induction of melanoma-antigen-specific CD8⁺ T cells via Vγ9γδT cell expansion by CD56^{high+} Interferon-α-induced dendritic cells. *Exp. Dermatol.* 24: 35–41.
<https://doi.org/10.1111/exd.12581>
- Parney, I. F. *et al.* (2009) Flow cytometry and *in vitro* analysis of human glioma-associated macrophages: Laboratory investigation. *J. Neurosurg.* 110: 572–582.
<https://doi.org/10.3171/2008.7.JNS08475>
- Pincha, M. *et al.* (2012) Identity, potency, *in vivo* viability, and scaling up production of lentiviral vector-induced dendritic cells for melanoma immunotherapy. *Hum. Gene Ther. Methods* 23: 38–55.
<https://doi.org/10.1089/hgtb.2011.170>
- Rasaiyaah, J. *et al.* (2009) Transcriptional and functional defects of dendritic cells derived from the MUTZ-3 leukemia line. *Immunology* 127: 429–441.
<https://doi.org/10.1111/j.1365-2567.2008.03018.x>
- Reinartz, S. *et al.* (2014) Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: Correlation of CD163 expression, cytokine levels and early relapse. *Int. J. Cancer* 134: 32–42.
<https://doi.org/10.1002/ijc.28335>
- Resheq, Y. J. *et al.* (2015) Contact-dependent depletion of hydrogen peroxide by catalase is a novel mechanism of myeloid-derived suppressor cell induction operating in human hepatic stellate cells. *J. Immunol.* 194: 2578–2586.
<https://doi.org/10.4049/jimmunol.1401046>
- Rodrigues, J. C. *et al.* (2010) Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. *Neuro Oncol.* 12: 351–365.
<https://doi.org/10.1093/neuonc/nop023>
- Romano, E. *et al.* (2015) Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells *ex vivo* by nonclassical monocytes in melanoma patients. *Proc. Natl. Acad. Sci. U. S. A.* 112: 6140–6145.
<https://doi.org/10.1073/pnas.1417320112>
- Schuler, P. J. *et al.* (2011) Dendritic cell generation and CD4⁺CD25^{high}FOXP3⁺ regulatory T cells in human head and neck carcinoma during radio-chemotherapy. *Eur. J. Med. Res.* 16: 57–62.
<https://doi.org/10.1186/2047-783x-16-2-57>
- Steensma, M. R. *et al.* (2013) Targeting the giant cell tumor stromal cell: functional characterization and a novel therapeutic strategy. *PLoS ONE* 8: 69101.
<https://doi.org/10.1371/journal.pone.0069101>
- Wang, J. *et al.* (2017) Surgery-induced monocytic myeloid-derived suppressor cells expand regulatory T cells in lung cancer. *Oncotarget* 8: 17050–17058.
<https://doi.org/10.18632/oncotarget.14991>
- Wen, Z. F. *et al.* (2018) Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1. *J. Immunother. Cancer* 6: 151.
<https://doi.org/10.1186/s40425-018-0452-5>
- Yaddanapudi, K. *et al.* (2016) MIF is necessary for late-stage melanoma patient MDSC immune suppression and differentiation. *Cancer Immunol. Res.* 4: 101–112.
<https://doi.org/10.1158/2326-6066.CIR-15-0070-T>
- Yamaguchi, T. *et al.* (2016) Tumor-associated macrophages of the M2 phenotype contribute to progression in gastric cancer with peritoneal dissemination. *Gastric Cancer* 19: 1052–1065.
<https://doi.org/10.1007/s10120-015-0579-8>
- Yu, J. *et al.* (2013) Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer. *J. Immunol.* 190: 3783–3797.
<https://doi.org/10.4049/jimmunol.1201449>

Myeloid cells in the tumor microenvironment (mouse)

Bunt, S. K. *et al.* (2006) Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. *J. Immunol.* 176: 284–290.
<https://doi.org/10.4049/jimmunol.176.1.284>

Dong, X. *et al.* (2020) Tumour-associated macrophages as a novel target of VEGI-251 in cancer therapy. *J. Cell. Mol. Med.* 24: 7884–7895.
<https://doi.org/10.1111/jcmm.15421>

Gabusiewicz, K. *et al.* (2011) Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas. *PLoS ONE* 6: 23902.
<https://doi.org/10.1371/journal.pone.0023902>

Gurusamy, D. *et al.* (2013) Myeloid-specific expression of Ron receptor kinase promotes prostate tumor growth. *Cancer Res.* 73: 1752–1763.
<https://doi.org/10.1158/0008-5472.CAN-12-2474>

Hart, K. M. *et al.* (2009) Phenotypic and functional delineation of murine CX3CR1⁺ monocyte-derived cells in ovarian cancer. *Neoplasia* 11: 564–73.
<https://doi.org/10.1593/neo.09228>

Ko, H. J. *et al.* (2007) A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. *Cancer Res.* 67: 7477–86.
<https://doi.org/10.1158/0008-5472.CAN-06-4639>

Ko, H.-J. *et al.* (2009) Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: an alternative cell-based anti-tumor vaccine. *J. Immunol.* 182: 1818–1828.
<https://doi.org/10.4049/jimmunol.0802430>

Li, L. N. *et al.* (2020) Helicobacter pylori infection reduces TAMs infiltration in a mouse model of AOM/DSS induced colitis-associated cancer. *PLoS ONE* 15: 0241840.
<https://doi.org/10.1371/journal.pone.0241840>

Lin, G. H. Y. *et al.* (2017) TTI-621 (SIRPaFc), a CD47-blocking cancer immunotherapeutic, triggers phagocytosis of lymphoma cells by multiple polarized macrophage subsets. *PLoS ONE* 12: 0187262.
<https://doi.org/10.1371/journal.pone.0187262>

Marhaba, R. *et al.* (2008) Opposing effects of fibrosarcoma cell-derived IL-1 α and IL-1 β on immune response induction. *Int. J. Cancer* 123: 134–145.
<https://doi.org/10.1002/ijc.23503>

Michel, A. *et al.* (2013) Mast cell-deficient kit (W-sh) “Sash” mutant mice display aberrant myelopoiesis leading to the accumulation of splenocytes that act as myeloid-derived suppressor cells. *J. Immunol.* 190: 5534–5544.
<https://doi.org/10.4049/jimmunol.1203355>

Müller, A. *et al.* (2015) Resident microglia, and not peripheral macrophages, are the main source of brain tumor mononuclear cells. *Int. J. Cancer* 137: 278–288.
<https://doi.org/10.1002/ijc.29379>

Nelson, N. *et al.* (2012) Preparation of myeloid-derived suppressor cells (MDSC) from naive and pancreatic tumor-bearing mice using flow cytometry and automated magnetic activated cell sorting (autoMACS). *J. Vis. Exp.* 18: 3875.
<https://doi.org/10.3791/3875>

Rodríguez, D. *et al.* (2013) Tumor microenvironment profoundly modifies functional status of macrophages: Peritoneal and tumor-associated macrophages are two very different subpopulations. *Cell. Immunol.* 283: 51–60.
<https://doi.org/10.1016/j.cellimm.2013.06.008>

Ryzhov, S. *et al.* (2011) Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b⁺Gr1⁺ cells. *J. Immunol.* 187: 6120–6129.
<https://doi.org/10.4049/jimmunol.1101225>

Sawanobori, Y. *et al.* (2008) Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. *Blood* 111: 5457–5466.
<https://doi.org/10.1182/blood-2008-01-136895>

Schmidt, K. *et al.* (2013) Differently immunogenic cancers in mice induce immature myeloid cells that suppress CTL *in vitro* but not *in vivo* following transfer. *Blood* 121: 1740–1748.
<https://doi.org/10.1182/blood-2012-06-436568>

Spear, P. *et al.* (2012) Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN- γ and GM-CSF. *J. Immunol.* 188: 6389–6398.
<https://doi.org/10.4049/jimmunol.1103019>

Szulzewsky, F. *et al.* (2015) Glioma-associated microglia/macrophages display an expression profile different from M1 and M2 polarization and highly express Gpnmb and Spp1. *PLoS ONE* 10: 0116644.
<https://doi.org/10.1371/journal.pone.0116644>

Thoreau, M. *et al.* (2015) Vaccine-induced tumor regression requires a dynamic cooperation between T cells and myeloid cells at the tumor site. *Oncotarget* 6: 27832–2746.
<https://doi.org/10.18632/oncotarget.4940>

Umehura, N. *et al.* (2008) Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. *J. Leuk. Biol.* 83: 1136–1144.
<https://doi.org/10.1189/jlb.0907611>

Vecchio, E. *et al.* (2020) IBTK haploinsufficiency affects the tumor microenvironment of myc-driven lymphoma in e-myc mice. *Int. J. Mol. Sci.* 21: 885.
<https://doi.org/10.3390/ijms21030885>

Virtuoso, L. P. *et al.* (2012) Characterization of iNOS⁺ neutrophil-like ring cell in tumor-bearing mice. *J. Transl. Med.* 10: 152.
<https://doi.org/10.1186/1479-5876-10-152>

Wang, L. C. S. *et al.* (2009) Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting agent DMXAA (ASA404). *Neoplasia* 11: 793–803.
<https://doi.org/10.1593/neo.09506>

Yan, H. H. *et al.* (2015) CCL9-induced by TGF- β -signaling in myeloid cells enhances tumor cell survival in the premetastatic organ. *Cancer Res.* 75: 5283–5298.
<https://doi.org/10.1158/0008-5472.CAN-15-2282-T>

Ye, C. *et al.* (2016) Targeting ornithine decarboxylase by α -Difluoromethylornithine inhibits tumor growth by impairing myeloid-derived suppressor cells. *J. Immunol.* 196: 915–23.
<https://doi.org/10.4049/jimmunol.1500729>

Zhang, J. Q. *et al.* (2018) Macrophages and CD8⁺ T cells mediate the antitumor efficacy of combined CD40 ligation and imatinib therapy in gastrointestinal stromal tumors. *Cancer Immunol. Res.* 6: 434–447.
<https://doi.org/10.1158/2326-6066.CIR-17-0345>

Zheng, Y. *et al.* (2019) Long noncoding RNA Pvt1 regulates the immunosuppression activity of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. *Mol. Cancer* 18: 61.
<https://doi.org/10.1186/s12943-019-0978-2>



Miltenyi Biotec provides products and services worldwide. Visit www.miltenyibiotec.com/local to find your nearest Miltenyi Biotec contact.

Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research use only and not for therapeutic or diagnostic use. The Miltenyi Biotec logo is a trademark of Miltenyi Biotec and/or its affiliates in various countries worldwide. Copyright © 2021 Miltenyi Biotec and/or its affiliates. All rights reserved.